According to the U.S. Centers for Disease Control and Prevention’s (CDC) most recent statistics, obesity is the number one health threat facing Americans, killing about 400,000 people each year with medical and other costs tipping the scale near $123 billion annually. Pressure Biosciences, Inc.’s (Nasdaq: PBIO) patented technology may come in useful in fighting America’s rising killer.
Pressure Biosciences’ pressure cycling technology (PCT) uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The technology has applications in genomics (the study of an organism’s hereditary information encoded in its DNA), proteomics (study of structures and functions of proteins) and nucleic acid testing with the ability to rupture cells to release significantly more proteins in fatty tissues.
As the battle of the bulge continues, Pressure Biosciences has expanded its product line, boosted its sales force, stacked up “ample” inventory and a has full service spectrum. The company intends on focusing on laboratories conducting obesity research using PCT because of its ability to extract proteins from lipid-rich tissue samples.
According to a Taglich Brothers report, the worldwide market for PCT, and other technologies developed by Pressure Biosciences, consists of 45,000 laboratories in various institutions. As demand for the development and production of more efficient drugs rises, so has the interest in proteomics.
Let us hear your thoughts below: Pressure BioSciences, Inc. Message Board